Orzeyful Approved by FDA as First Orexin Therapy for Narcolepsy Type 1
KEY TAKEAWAYS
- The FDA approved Orzeyful, an oral orexin receptor 2 agonist, for adults with narcolepsy type 1.
- Orzeyful is the first approved orexin-targeting therapy for narcolepsy type 1, a disorder driven by orexin deficiency.
The Food and Drug Administration (FDA) has approved Orzeyful (oveporexton; Takeda, Osaka, Japan, and Cambridge, MA), an oral orexin receptor 2 (OX2R) agonist, for the treatment of adults with narcolepsy type 1. Takeda stated that the medication will become available in the United States after the Drug Enforcement Administration completes controlled substance scheduling, which the company expects within 90 days.
Narcolepsy type 1 is a chronic neurologic disorder associated with orexin deficiency and characterized by excessive daytime sleepiness, cataplexy, cognitive symptoms, and disrupted nighttime sleep. According to an announcement from Takeda, Orzeyful is designed to activate OX2R signaling, with the goal of addressing the orexin pathway underlying narcolepsy type 1 rather than targeting individual symptoms alone.
Approval Highlights
- Orzeyful is indicated for adults with narcolepsy type 1.
- The approval was supported by data from the global phase 3 FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies.
- In those trials, treatment with Orzeyful was associated with statistically significant improvements in symptoms including excessive daytime sleepiness, cataplexy, and health-related quality of life compared with placebo.
- Takeda reported that oveporexton was generally well tolerated across studies.
- The most common adverse events included insomnia, urinary urgency, urinary frequency, and excessive saliva.
“Until now, people have managed narcolepsy type 1 with treatments that target symptom relief,” said Dr. Emmanuel Mignot, MD, PhD, Principal US Investigator in the Orzeyful phase 3 program. “As the first and only approved orexin therapy to treat the broad spectrum of the disease, Orzeyful can enable a different kind of conversation in the doctor’s office about treatment options.”
According to Takeda, Orzeyful is expected to be distributed through a specialty pharmacy after controlled substance scheduling is finalized.
Source
Takeda. U.S. FDA approves Takeda’s Orzeyful (oveporexton), the first and only medicine to treat the underlying cause of narcolepsy type 1. Published August 5, 2026. Accessed August 6, 2026. https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-narcolepsy/